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The pancreatic beta cell synthesizes and secretes ap-
propriate amounts of insulin to allow correct regula-
tion of blood glucose levels in non-diabetic indivi-
duals. In the short term, the beta cell releases precise
quantities of insulin in response to minute-to-minute
changes in blood glucose. In the long term, beta cells
adapt to metabolic changes such as the insulin resis-
tance associated with obesity by appropriately alter-
ing insulin synthesis and beta-cell mass. Defects in in-
sulin production – from its synthesis through to its se-
cretion – by the beta cell have been implicated in the
pathophysiology of both insulin-dependent (IDDM)
and non-insulin-dependent (NIDDM) diabetes melli-
tus. Recent investigations focussed on the biology of
the beta cell have led to an explosion of new informa-
tion on the pathways involved in insulin synthesis and
secretion and how defects in these pathways might be
implicated in the pathogenesis of diabetes. Thus, for
example, during the past few years we have gained a
further understanding of the regulation of insulin
gene transcription and the development of normal
differentiated beta-cell function; the important role
of translational control in the regulation of proinsulin
biosynthesis; the molecular physiology of the ion
channels involved in the coupling of beta-cell glucose
metabolism with insulin secretion; and the exocytotic
machinery employed by beta cells to secrete insulin
granules. Each of the genes encoding a protein in-
volved in insulin production, from its biosynthesis to
its release, represents a candidate susceptibility gene
for diabetes; indeed, several recently identified genes
associated with diabetes encode proteins that appear
to play important roles in normal beta-cell function.
Through improving our knowledge of the mechanism
of insulin production by the beta cell, we will un-
doubtedly gain new insight into the pathogenesis of
diabetes. We report here highlights from recent re-
search devoted to the study of beta-cell biology.
Michael German: Transcriptional control of proinsulin
biosynthesis and beta-cell differentiation
To fulfil their role as nutrient sensors and metabolic
regulators, beta cells must express a set of specialized
gene products, the most obvious being insulin. These
genes start to be expressed as the beta cells develop
from the intestinal epithelium and differentiate from
the surrounding exocrine and endocrine cells. Both
the process of development and the maintenance of
the differentiated state are dependent on a unique
set of transcription factor genes expressed in the
beta cell.
It is important to understand that although they
may activate transcription of beta-cell-specific genes,
none of the beta-cell transcription factors are them-
selves expressed exclusively in beta cells. Instead the
transcription factors have distinct but overlapping ex-
pression patterns that result in a set of factors that is
absolutely unique to the beta cell. The transcription
factors that compose this unique beta-cell set then in-
teract to form unique functional complexes capable
of activating beta-cell-specific genes such as insulin.
Michael German and his colleagues at the Univer-
sity of California, San Francisco, have used insulin
gene transcription as a paradigm of beta-cell specific
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gene expression. The proximal (about 400 bp) insulin
promoter is remarkably complex, with multiple se-
quence elements along its length. Because each of
these sequence elements forms a recognition site for
binding of beta-cell transcription factors, the promo-
ter determines the structure of a transcriptional acti-
vation complex that can only be formed by the
unique set of transcription factors found in the beta-
cell nucleus.
Understanding the insulin gene, therefore, re-
quires an understanding of the beta-cell transcription
factors. The beta cells express multiple transcription
factors, including many members of the basic helix-
loop-helix, winged helix, zinc finger, and homeodo-
main families of transcription factors. Among the
homeodomain transcription factors expressed in
beta cells are members of the hox, Lim, pou, Nkx,
cdx, pdx and paired families [1, 2].
As an example of a beta-cell transcription factor,
Dr. German’s laboratory has studied the expression
and function of the paired homeodomain factor
pax 6. The pax family of vertebrate transcription fac-
tor genes is related to the Drosophila paired gene
and shares a conserved sequence motif, the paired
box, that encodes a DNA-binding domain. In addi-
tion to the pancreas, pax 6 is expressed in a variety
of tissues, including the eye and the central nervous
system. The importance of pax 6 in eye development
has been demonstrated by the effect of mutations in
Drosophila, rodents and humans. In mice, for exam-
ple, mutation of pax 6 causes a syndrome termed
small eye (Sey) because heterozygous animals have a
reduction in eye size, while animals homozygous for
the sey mutation have a complete disruption of eye
development and severe craniofacial abnormalities
and die at birth.
Dr. German and colleagues have observed that ex-
pression of pax 6 precedes that of the earliest pan-
creatic endocrine markers in the developing mouse
embryo and remains restricted to cells of endocrine
lineage throughout pancreatic development and in
the adult pancreas. Homozygous small eye (Seyneu)
mice have abnormal islet morphology and marked
decreases in the numbers of all four islet cell types.
In addition, islet morphology is disordered.
In the homozygous Seyneu embryo, insulin and,
more strikingly, glucagon production is severely atte-
nuated due to decreased gene transcription. Pax 6
binds to crucial elements in the glucagon, insulin and
somatostatin promoters; and pax 6, but not the Seyneu
(mutant pax 6) protein, activates insulin and gluca-
gon transcription. These results demonstrate that
pax 6 plays an important role both in islet develop-
ment and in hormone gene transcription.
The remarkable effects of pax 6 on insulin gene
expression underscore the importance of a complete
set of transcription factors for full expression of
the insulin gene. Despite the presence of multiple
transcription factors in beta cells, the removal of a
single factor can cripple the transcriptional activation
complex. The understanding of both beta cell devel-
opment and insulin gene transcription will require
further studies of the expression and function of the
beta-cell transcription factors. Such studies must in-
clude identification of the full set of beta-cell tran-
scription factors, determination of their roles in de-
velopment, and dissection of the interactions among
transcription factors that produce the beta-cell tran-
scription activation complexes.
Christopher Rhodes: Translational control of proinsulin
biosynthesis
Following gene transcription, proinsulin biosynthesis
is subject to further regulation at the level of transla-
tion. The importance of translational control in the
normal regulation of proinsulin biosynthesis is be-
coming increasingly apparent from work performed
by Christopher Rhodes and his colleagues at the Uni-
versity of Texas Southwestern Medical Center. In the
short term ( < 2 h), glucose-stimulated proinsulin bio-
synthesis is regulated largely at the translational lev-
el. Thus, a 30-fold increase in proinsulin biosynthesis
induced by glucose can be observed in just 1 h, yet
even after 6 h only a 2–3 fold glucose stimulation in
preproinsulin mRNA levels is seen [3]. Since in-
creased proinsulin biosynthesis places increased de-
mand on proinsulin conversion, the beta cell compen-
sates by a co-ordinated parallel glucose regulation of
the biosynthesis of the prohormone convertase en-
zymes (PC1(3) and PC2), also at the translational lev-
el [4].
Although levels of preproinsulin mRNA do not
change dramatically in response to glucose in the
short term, there is a subcellular redistribution of pre-
proinsulin mRNA following glucose stimulation. Dr.
Rhodes has found that glucose rapidly decreases
(within 30 min) the cytosolic pool of preproinsulin
mRNA while correspondingly increasing first the
free polysomal associated preproinsulin mRNA, fol-
lowed by an increase in the membrane-bound polyso-
mal pool of preproinsulin mRNA (the major site of
proinsulin biosynthesis in the beta cell). Glucose-in-
duced ribosomal attachment to preproinsulin
mRNA implies specific regulation at the initiation
phase of translation.
Initiation of protein synthesis is known to be regu-
lated by phosphorylation of eukaryotic initiation fac-
tors. However, no known eukaryotic initiation factors
have yet been found to be phosphorylated in a way
that correlates with the specific stimulation of proin-
sulin mRNA translation by glucose. Consequently,
the presence of nutrient regulatory elements in the
5 ¢ - and 3 ¢ -untranslated regions of preproinsulin
mRNA has been proposed. While such elements
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have not yet been functionally identified, there are
conserved regions in the untranslated regions of pre-
proinsulin mRNA which are consistent with that hy-
pothesis, including a ‘stem loop’ secondary structure
in the 5 ¢ -untranslated region and a highly conserved
primary sequence in the 3 ¢ -untranslated region,
downstream of the polyadenylation signal.
The intracellular mediators coupling glucose me-
tabolism in the beta cell to increased translation of
preproinsulin mRNA also remain to be elucidated.
Dr. Rhodes has outlined that none of the factors
thought to be involved in coupling glucose metabo-
lism to insulin secretion in the beta cell (e.g. ATP/
ADP, [Ca2 + ]i; see later) appear to be involved. Pre-
liminary data suggest that specific changes in the re-
dox state of the beta cell, as reflected by a decreased
cytosolic NAD(P)H:NAD(P) ratio, may be in-
volved.
As detailed in another report in this supplement,
the important role of non-esterified fatty acids
(NEFA) in the regulation of beta-cell function is be-
coming increasingly apparent. Interestingly, NEFA
inhibit glucose-stimulated translation of preproinsu-
lin mRNA, in marked contrast to the acute potentia-
tion of glucose-induced insulin secretion by these
agents. In isolated islets cultured in the presence of
NEFA for 24 h, insulin content decreases by 50%
due to a fatty acid-induced increase in basal insulin
secretion accompanied by a decrease in proinsulin
mRNA translation. Thus, proinsulin biosynthesis fails
to compensate for the fatty acid-induced insulin se-
cretion. This finding may have implications for under-
standing the pathogenesis of beta-cell dysfunction in
NIDDM, in which a role for NEFA has been impli-
cated, and in which insulin secretion is increased but
content is likely decreased. The decrease in insulin
content induced by exposure of islets to NEFA occurs
despite an increase in proinsulin gene expression, fur-
ther emphasizing the importance of translation in the
maintenance of insulin content.
Frances Ashcroft: The role of ion channels in insulin
secretion
As reported by Frances Ashcroft of Oxford Universi-
ty, ATP-sensitive potassium channels (KATP chan-
nels) couple cell metabolism to electrical activity
and play important roles in the physiology and patho-
physiology of many tissues [5]. In pancreatic beta
cells, the KATP channel regulates insulin secretion
both in response to glucose – the primary physiologi-
cal stimulus – and to clinically important drugs. Muta-
tions in this channel cause persistent hyperinsulinae-
mic hypoglycaemia of infancy (PHHI), a disease
associated with unregulated hypersecretion of insu-
lin. Defective regulation of KATP channel activity,
as a result of compromised beta-cell metabolism is
associated with certain forms of maturity onset dia-
betes of the young (MODY).
The consensus view of beta-cell stimulus-secretion
coupling is that when plasma glucose levels rise, glu-
cose uptake and metabolism by the beta cell is in-
creased. The resulting elevation of intracellular ATP,
and concomitant lowering of intracellular MgADP,
closes KATP channels in the beta-cell plasma mem-
brane, because ATP inhibits, whereas MgADP acti-
vates, channel activity. This produces a membrane de-
polarisation which activates voltage-dependent Ca2 +
channels, increases Ca2 + influx into the beta cell and
triggers insulin release. KATP channels are also regula-
ted by two clinically important classes of drugs. Sul-
phonylureas, widely used in the treatment of NIDDM,
inhibit KATP channel activity and thereby stimulate in-
sulin release. By contrast, K-channel openers, such as
diazoxide, activate KATP channels thereby hyperpolar-
izing the beta cell and inhibiting insulin release. Diaz-
oxide is sometimes used to treat PHHI.
The beta-cell KATP channel is a complex of two
proteins: Kir6.2 and SUR1. Kir6.2 serves as the
KATP channel pore whereas the sulphonylurea recep-
tor SUR1 acts as a regulator of channel activity con-
ferring sensitivity to sulphonylureas and diazoxide.
SUR1 belongs to a family of ATP-binding cassette
transporters and, like other members of this family,
has two large cytoplasmic domains which contain
highly conserved consensus sequences for nucleotide
binding. This suggests that the nucleotide binding do-
mains (NBDs) of SUR1 may constitute one or more
of the sites at which nucleotides regulate KATP chan-
nel activity. Dr. Ashcroft and colleagues have there-
fore mutated (independently or together) two lysine
residues (the WA lysines), one in the first (K719A)
and one in the second (K1385M) NBDs of SUR1 [6].
These mutations are expected to abolish ATP hydrol-
ysis without affecting nucleotide binding.
Their results indicate that neither WA lysine resi-
due is required for channel inhibition by ATP: in-
deed, mutant currents were slightly more sensitive to
ATP than wild-type currents. ADP has both stimula-
tory and inhibitory actions on wild-type KATP cur-
rents (as demonstrated by the fact that MgADP acti-
vates, whereas free ADP inhibits, channel activity).
Dr. Ashcroft’s group has further shown that the abil-
ity of MgADP to potentiate KATP currents required
the presence of the WA lysine in both NBDs. Inhibi-
tion of KATP currents by ADP, like that of ATP, did
not require the WA lysines. The guanine nucleotides,
MgGDP and MgGTP, also stimulated wild-type but
not WA mutant currents. Although their data argue
that the WA lysine residues are required for MgADP
(or MgGDP) binding to produce a conformational
change which leads to channel activation, they do
not allow a conclusion as to whether or not this con-
formational change requires nucleotide diphosphate
hydrolysis.
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KATP channel regulation by MgADP plays a cen-
tral role in coupling changes in beta-cell metabolism
to channel activity. Recent results indicate that this
regulation is achieved by the NBDs of SUR1, which
in some way influence the opening of the Kir6.2
pore. Metabolic inhibition led to activation of wild-
type but not K719A or K719A/K1385M currents, sup-
porting the idea that MgADP plays an essential role
in metabolic regulation of the KATP channel.
The stimulatory effect of diazoxide requires the
presence of hydrolysable nucleotide at the inner mem-
brane surface. Dr. Ashcroft’s results indicate that the
WA lysine at NBD1 is essential for activation of KATP
currents by diazoxide, while that at NBD2 has an en-
hancing role. This suggests that a conformational
change induced by nucleotide binding or hydrolysis
at NBD1 is involved in diazoxide action. Dr. Ashcroft
also found that MgGDP was more effective at sup-
porting diazoxide action than MgGTP, which argues
that interaction of nucleotide diphosphates with the
NBDs of SUR1 induces this conformational change
more readily than nucleotide triphosphates.
These studies clarify the mechanism of action of
nucleotides on KATP channels and demonstrate that
the WA lysines within the NBDs of SUR1 play an es-
sential role in channel activation by MgADP,
MgGDP and diazoxide.
Romano Regazzi: Molecular mechanism of insulin
exocytosis
The fine tuning of insulin secretion from pancreatic
beta cells is essential for blood glucose homeostasis.
Molecular dissection of the exocytotic event is a pre-
requisite to understand how secretagogues such as
glucose stimulate insulin release and how such regu-
lation becomes deranged in disease states. As report-
ed by Romano Regazzi of the University of Lau-
sanne, although much remains to be done until the
detailed mechanism underlying insulin secretion is
elucidated at the molecular level, studies performed
during the last couple of years have brought an extra-
ordinary development in our knowledge about the
basic components of the exocytotic machinery in pan-
creatic beta cells.
Advances in different research fields, including re-
constitution of vesicular trafficking in cell-free sys-
tems, studies on the mode of action of clostridial neu-
rotoxins and genetic studies in yeast have led to the
formulation of a general model to explain how secre-
tory vesicles in eukaryotes are targeted and fuse with
the appropriate acceptor membrane [7]. This is a fun-
damental issue since secretory products such as insu-
lin travel in a highly regulated fashion from the endo-
plasmic reticulum to the Golgi apparatus and from
there toward the plasma membrane. According to
this model each secretory vesicle possesses at least
one protein that functions as a vesicular SNAP recep-
tor (v-SNARE). The v-SNARE interacts specifically
with protein(s) located on the targeted membrane,
the target SNAP receptor(s) (t-SNARE). The com-
plex formed between v- and t-SNAREs serves two
functions: first, the specific pairing between proteins
located on the secretory vesicle and on the acceptor
membrane ensures correct targeting of the vesicle;
second, the SNARE complex creates a kind of scaf-
fold that permits the recruitment of cytosolic compo-
nents required for vesicle fusion. During the last
2 years both the v-SNAREs of insulin-containing se-
cretory granules and the t-SNAREs located at the
plasma membrane of pancreatic beta cells have been
identified [7]. Insulin-secretory granules carry two v-
SNAREs belonging to the VAMP/synaptobrevin fa-
mily, VAMP-2 and cellubrevin, while SNAP-25 and
syntaxin-I are associated with the plasma membrane
[7]. The involvement of these proteins in insulin exo-
cytosis was demonstrated using the neurotoxins pro-
duced by Clostridium tetani (TeTx) and Clostridium
botulinum (BoNT). These neurotoxins are zinc-de-
pendent proteases with a unique substrate specificity.
Thus, BoNT serotype B, D and F cleave VAMP pro-
teins (both VAMP-2 and cellubrevin), BoNT A and
E cut SNAP-25 while BoNT C cleaves syntaxin-I.
The introduction of each of these neurotoxins in per-
meabilized cells (pancreatic beta cells do not express
the neurospecific receptors for the toxins) results in
a block of Ca2 + -triggered exocytosis clearly demon-
strating that VAMPs, SNAP-25 and syntaxin-I are re-
quired for insulin secretion [7]. Secretory granules of
pancreatic beta cells possess two v-SNAREs that are
cleaved equally well by clostridial neurotoxins. Thus,
using this approach it was not possible to assess the
implication of each of the two VAMP isoforms in in-
sulin exocytosis. For this purpose a different strategy
was designed by Regazzi and colleagues to analyse
the respective roles of VAMP-2 and cellubrevin in
the control of insulin release [8]. Each of the two iso-
forms was made resistant to TeTx proteolysis by
modifying the amino acids at the cleavage site and
was then transfected in insulin-secreting cells. The
transfected cells were permeabilized and treated
with TeTx to inactivate the endogenous VAMPs but
not their genetically engineered counterparts whose
cleavage site for the toxin was modified. Using this
technique VAMP-2 and cellubrevin were found to re-
constitute equally well Ca2 + -evoked secretion in
TeTx-treated cells indicating that both VAMPs are
implicated in the control of insulin exocytosis [8]. De-
letion mutations of VAMP proteins preventing the
binding to SNAP-25 and/or syntaxin-I rendered the
proteins inactive, confirming that the interaction be-
tween v- and t-SNAREs is an essential requirement
for the exocytotic process [8].
Ras-like GTPases of the Rab family are implicated
in vesicular trafficking and are required for each step
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along the secretory pathway [7]. The precise mode of
action of Rab proteins is not yet fully understood
but these GTPases are believed to contribute to the
specificity of vesicle targeting. A current model pro-
poses that Rab proteins favour or stabilize the inter-
action between v- and t-SNAREs enabling secretory
vesicles to reach their proper destination. Pancreatic
beta cells express several members of the Rab family
associated with different cellular compartments. In
particular, different Rab3 isoforms are associated
with insulin-containing secretory granules [7]. To de-
monstrate a functional role of Rab3 proteins in the
regulation of insulin secretion, HIT-T15 were trans-
fected with wild-type Rab3A and with a GTPase defi-
cient mutant of this Rab protein. Overexpression of
wild-type Rab3A did not affect basal secretion but re-
sulted in a small inhibition of nutrient-evoked insulin
release. This inhibition was much more pronounced
in cells transfected with the GTPase deficient mutant
of Rab3A. Thus, GTP hydrolysis by Rab3A is essen-
tial for the exocytotic process of beta cells.
The investigations performed during the last cou-
ple of years have thus led to the identification of sev-
eral proteins required for the targeting and fusion of
insulin-containing secretory granules with the plasma
membrane. The next challenge will be to understand
how physiological stimuli are able to modulate the
exocytotic machinery of pancreatic beta cells.
Alan Permutt: Beta-cell genes in diabetes
Genes encoding beta-cell proteins are attractive can-
didates for susceptibility genes for both IDDM and
NIDDM. This seems especially true for NIDDM, as
there is considerable evidence to suggest that
NIDDM is a polygenic disease in which genetic de-
fects in beta-cell function are present. M. Alan Per-
mutt and his colleagues at Washington University in
St. Louis are using a molecular genetic approach to
uncover the aetiology of NIDDM by investigating
the hypothesis that while insulin resistance is a major
component of the disease, those individuals with de-
fects in insulin production are at greatest risk. Such
studies typically utilize a number of genetic methods
which are integrated with the development of the Hu-
man Genome Project. One such approach is to use hu-
man islet cDNA libraries to identify novel islet genes
[9]. In recent years, these libraries have been used to
isolate a number of genes involved in insulin biosyn-
thesis and secretion, including the rate-limiting pro-
teins for islet glucose metabolism, the islet glucose
transporter GLUT2 and the islet glucose phosphory-
lating enzyme glucokinase. Other islet cDNAs isolat-
ed and characterized include mitochondrial glycerol-
phosphate-dehydrogenase (mGPDH), the sulfonyl-
urea receptor (SUR), the ATP-regulated potas-
sium channel Kir6.2, and several other unique islet
potassium channel genes including Girk 1, Girk 2,
Cir, and a calcium-activated potassium channel hSlo.
Once the cDNA for a beta-cell gene has been iso-
lated, several approaches can be used to determine
whether this represents a diabetes gene. For example,
one can identify genomic clones with nearby microsa-
tellite markers and place the genes on physical maps
using radiation hybrid and yeast artificial chromo-
some (YAC) contig mapping, then look for linkage
in families or screen known diabetic loci. In addition,
a number of beta-cell genes have now been screened
by Dr. Permutt and others for single nucleotide chan-
ges in diabetic patients by single-strand conforma-
tional polymorphic analysis (SSCP) and direct geno-
mic sequencing. Several mutations have been found
in the glucokinase gene which are responsible for a
large fraction of MODY, a relatively rare form of
NIDDM. A single mutation was found in the islet
glucose transporter which completely eliminated glu-
cose entry, defining a unique portion of the protein
required for glucose transport. Variants of mGPDH,
SUR [10], and KATP channels were also identified,
and SUR variants were found to be significantly asso-
ciated with NIDDM.
A number of islet transcription factors have re-
cently been identified which appear to be important
in regulation of insulin biosynthesis. Dr. Permutt’s
group has isolated human clones of the genes encod-
ing these transcription factors, identified genomic
structure and mapped their chromosomal localiza-
tion, and they are currently in the process of screen-
ing diabetic patients for mutations in these genes. Is-
let transcription factors such as Nkx6.1/Nkx 6A, Isl1,
and Pdx 1 represent good candidates for NIDDM
genes, since this disease is characterized by a failure
to increase beta-cell mass and insulin production in
the presence of insulin resistance. In this regard, it is
interesting to note that mutations in hepatic nuclear
factor (HNF)1a, a transcription factor expressed in
islets, have been identified in patients with MODY3,
a group who are known to have impaired insulin se-
cretion. Exon 4 of the HNF1a gene appears to con-
tain a mutational hotspot, as 30–40 different muta-
tions have recently been found in this region of the
gene. Whether the HNF1a gene or indeed genes en-
coding other islet transcription factors play a role in
more common forms of NIDDM remains to be deter-
mined; Dr. Permutt has now sequenced the HNF1a
gene in 24 diabetic Ashkenazi Jews, and found a non-
sense mutation in one individual.
An additional strategy for identification of novel
islet genes has been the use of differential display of
islet mRNA. A major limitation of islet cDNA librar-
ies is the presence of contamination by cDNAs en-
coding proteins expressed in exocrine pancreas. To
circumvent this problem, Permutt and colleagues are
using differential display to identify, clone, and
sequence genes uniquely expressed in islet mRNA
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relative to pancreatic exocrine tissue. These islet ex-
pressed sequence tags (ESTs) have been compared
to sequences in public databases. In several cases, in-
teresting previously known genes such as the cal-
cium-activated potassium channel and a DNA heli-
case have been identified, as well as a new sulfotrans-
ferase which might play a role in sex steroid/glucocor-
ticoid metabolism in islets. In addition, they have
identified over 40 novel islet ESTs which have been
placed in the human genetic map. These novel islet
ESTs will be useful for positional cloning of NIDDM
genes.
Positional cloning represents an additional ap-
proach to identifying diabetes genes that is useful in
monogenic disorders. Using positional cloning, Dr.
Permutt’s group successfully mapped a monogenic
disorder of insulin secretion, that of Familial Hyper-
insulinism. Children with this condition are born
with severe hypoglycaemia and uncontrolled insulin
secretion. After performing a whole genome search
with anonymous markers and mapping the disease
to the short arm of chromosome 11, a candidate
gene, the sulfonylurea receptor, was mapped to this
region. This gene was subsequently shown to be a reg-
ulatory component of the KATP channel. Dr. Permutt
has now characterized the SUR gene and the Kir6.2
gene in approximately 100 probands with Familial
Hypoglycaemia, and has identified 19 mutations in
these genes (unpublished data), including one child
with a homozygous nonsense mutation in the KATP
channel. This child presents the first functional
knockout of the Kir6.2 gene found in man.
Conclusion
Thanks to basic research on the biology of the beta
cell, we have moved much closer to a complete un-
derstanding of the fundamental mechanisms involved
in insulin synthesis and secretion. Such information
will be critical to the future development of any novel
therapies for the treatment of diabetes. Indeed, it is
only after having a clear picture of how the normal
beta-cell functions that we will be able to devise ef-
fective pharmacological agents which act on the dia-
betic beta cell or to bioengineer surrogate beta cells.
Through this work we have also furthered our under-
standing of how mutations in beta-cell proteins may
lead to diabetes and have identified novel proteins in-
volved in insulin production, some of which represent
excellent new candidate genes for diabetes.
Despite the remarkable progress made over the
past few years, it is clear that much more work is need-
ed before the most intimate mysteries of the beta cell
are revealed and exploited for therapeutic purposes.
Future work in the areas of research discussed above
and with a view to improved treatment and/or preven-
tion of diabetes are envisaged to include:
Future directions and recommendations
• Increase our basic understanding of the promoter
elements and transcription factors involved in insulin
gene transcription and beta-cell differentiation and
how these elements may be involved in the beta-cell
adaptation to insulin resistance.
• Define the mechanism of stimulus-translation cou-
pling by which nutrient metabolism regulates transla-
tion of proinsulin and other mRNAs in the beta cell.
• Identify the ion channels that maintain the resting
membrane potential and the bursting activity of beta
cells.
• Elucidate how calcium and other factors interact
with SNARE proteins in order to stimulate exocyto-
sis of insulin granules.
• Identify novel beta-cell genes involved in diabetes.
• Establish a catalogue of “minimal essential” pro-
teins indispensable for achieving regulated insulin se-
cretion and necessary for the creation of surrogate
beta cells.
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